It was first approved by the FDA for HER2-positive metastatic breast cancer in 2013, and subsequently in 2019 it was approved in the adjuvant setting for early-stage HER2-positive breast cancer with residual invasive disease after neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.